Good ol' Carl helping the cause today!
Everyone should ask their doctor not to send the script to Express Scripts and fill it elsewhere. Its crazy that we have to go to another country now in order to get the medication we need! This is plum nuts!!!
Apple just wins a 10 year old lawsuit but instead of soaring on the good news it retreats because a few damned Russians are halted from online sales! Mind blowing BS!
...09:55 AM EST, 12/26/2014 (MT Newswires) -- Gilead Sciences ( GILD ) shares climbed Friday morning after RBC Capital said the biopharmaceutical firm could launch a new share buyback program of $5 billion to $10 billion over the next year after finishing its current $5 billion buyback plan over the next couple of months.
The broker said a new $5 billion to $10 billion share buyback would "make easy financial sense," as it would be a smart way to use "billions of cash building up right now," and provide "confidence to the market that there are no fundamental changes to the outlook," Seeking Alpha reported.
RBC Capital noted how GILD shares fell recently following news that Express Scripts ( ESRX ) sealed an exclusive HCV deal with AbbVie ( ABBV ) . The broker said the agreement will only impact approximately 2% to 10% of the HCV market, and that GILD stock will ultimately recover.
GILD shares were up 2.7% at $93.77 in recent morning trading, within a 52-week range of $63.50 to $116.83.
Price: 93.78, Change: +2.49, Percent Change: +2.73
"...In making a presentation to a crowd of investors at the conference Tuesday, Gilead President and Chief Operating Officer John Milligan talked extensively about the company’s finances and a number of other products before turning the subject to their formidable hepatitis C drugs. But he was unapologetic.
“I saved the best for last,” Milligan said.
Indeed, Sovaldi’s phenomenal takeoff produced $7.3 billion in sales for the company during the first nine months of 2014, Milligan said, helping to double Gilead’s overall revenue in one year to $20 billion as of Sept. 30. He said that more than 100,000 patients have been approved and the drug is now broadly covered. It’s also included in the Veterans’ Administration formulary and is widely sold under a contract with drugstore giant CVS Health. CVS, +0.05%
2 medical conferences, one tomorrow and one on Wednesday. They gotta talk up the pipeline after giving lousy guidance at the earnings release. JMO but seems oversold to me.
Monday we may see the case get thrown out! AAPL has been fighting this battle for 10 years. Could be a relief rally in the making if this goes away!
let the baxxturds have their day! Pre-earnings run-up to begin soon and longs will be back in the saddle!
I wish I'd gotten out at 110. This CEO is very inexperienced. I guess that's what you get when you make an old school teacher a CEO! NEVER AGAIN!!! Took a 8500 loss but I'm glad to be out! With a miss of this size, its going to take time to dig back out of the hole. Shame on Jack Ma! I should have listened to "The Donald!"
...08:35 AM EST, 02/09/2015 (MT Newswires) -- Canaccord Genuity boosted its price target on Apple ( AAPL ) shares today to $145 from $135. The analyst noted that as Apple ( AAPL) dominated the smartphone market in Q4 and calendar 2014, it's growing iPhone user base should drive steady long-term iPhone sales and strong cash flows.
AA...The aluminium maker reported adjusted earnings per share of 33 cents, up from 4 cents a share in the year-earlier period, and beating analysts' forecast. Revenue also beat expectations at $6.38 billion, up from from $5.59 billion a year ago.
Wall Street had expected Alcoa to deliver quarterly earnings per share of 29 cents on $6.04 billion in revenue, according to a consensus estimate from Thomson Reuters.
This selloff has been overdone imo!